Imidazole → tert-butyl(1-(4-(1-((1H-imidazol-5-yl)methyl)-2-oxo-7-phenyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)phenyl)cyclobutyl)carbamate

In a round bottom flask was added tert-butyl 1-(4-(2-oxo-7-phenyl-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-6-yl)phenyl)cyclobutylcarbamate (150 mg, 0.318 mmol) in DMF (Volume: 8 ml) to give a brown solution.sodium hydride (30.5 mg, 0.763 mmol) and 5-(chloromethyl)-1H-imidazole hydrochloride salt (58.4 mg, 0.501 mmol) was added. The resulting mixture was stirred at room temperature for 2 h. further sodium hydride (15.2 mg) and imidazole (29 mg) were added and the resulting mixture stirred for another hour. The reaction mixture was concentrated to dryness. The residue was partitioned between ethyl acetate (35 ml) and water (30 ml). The organic phase was separated and washed with water (2×25 ml), brine and concentrated. The residue was purified by column (biotage 25 g) to give product (14 mg). LCMS (Method A) RT=4.58 min, M+H+=552.1.

1. customto give a brown solution
2. additionwere added
3. concentrationThe reaction mixture was concentrated to dryness
4. customThe residue was partitioned between ethyl acetate (35 ml) and water (30 ml)
5. customThe organic phase was separated
6. washwashed with water (2×25 ml), brine
7. concentrationconcentrated
8. customThe residue was purified by column (biotage 25 g)

ORD 기록

ord-3c380b64155d4dabac91fe80c89ec6df

출처 데이터셋

uspto-grants-2015_12

DOI

10.6084/m9.figshare.5104873.v1

특허 번호

US09221838B2